Efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide containing antiretroviral therapy in virologically suppressed HIV-infected patients
Not Applicable
- Conditions
- HIV infection
- Registration Number
- JPRN-UMIN000038177
- Lead Sponsor
- Kyushu University Hospital Department of General internal medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
Patients are inadequate to include in this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy for maintenance of virological suppression in HIV-infected patients 48 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide containing antiretroviral therapy.
- Secondary Outcome Measures
Name Time Method Efficacy for improvement of renal function and bone metabolism markers, rate of new HBV infection 48 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide containing antiretroviral therapy.